38474719|t|Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives.
38474719|a|Amyotrophic Lateral Sclerosis (ALS) is a highly fatal neurodegenerative disorder characterized by the progressive wasting and paralysis of voluntary muscle. Despite extensive research, the etiology of ALS remains elusive, and effective treatment options are limited. However, recent evidence implicates gut dysbiosis and gut-brain axis (GBA) dysfunction in ALS pathogenesis. Alterations to the composition and diversity of microbial communities within the gut flora have been consistently observed in ALS patients. These changes are often correlated with disease progression and patient outcome, suggesting that GBA modulation may have therapeutic potential. Indeed, targeting the gut microbiota has been shown to be neuroprotective in several animal models, alleviating motor symptoms and mitigating disease progression. However, the translation of these findings to human patients is challenging due to the complexity of ALS pathology and the varying diversity of gut microbiota. This review comprehensively summarizes the current literature on ALS-related gut dysbiosis, focusing on the implications of GBA dysfunction. It delineates three main mechanisms by which dysbiosis contributes to ALS pathology: compromised intestinal barrier integrity, metabolic dysfunction, and immune dysregulation. It also examines preclinical evidence on the therapeutic potential of gut-microbiota-modulating agents (categorized as prebiotics, probiotics, and postbiotics) in ALS.
38474719	26	55	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
38474719	99	128	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
38474719	130	133	ALS	Disease	MESH:D000690
38474719	153	179	neurodegenerative disorder	Disease	MESH:D019636
38474719	225	254	paralysis of voluntary muscle	Disease	MESH:D012133
38474719	300	303	ALS	Disease	MESH:D000690
38474719	402	415	gut dysbiosis	Disease	MESH:D064806
38474719	420	434	gut-brain axis	Disease	MESH:C566610
38474719	436	440	GBA)	Disease	MESH:C566610
38474719	456	459	ALS	Disease	MESH:D000690
38474719	600	603	ALS	Disease	MESH:D000690
38474719	604	612	patients	Species	9606
38474719	678	685	patient	Species	9606
38474719	711	714	GBA	Disease	MESH:C566610
38474719	967	972	human	Species	9606
38474719	973	981	patients	Species	9606
38474719	1022	1025	ALS	Disease	MESH:D000690
38474719	1146	1149	ALS	Disease	MESH:D000690
38474719	1158	1171	gut dysbiosis	Disease	MESH:D064806
38474719	1205	1208	GBA	Disease	MESH:C566610
38474719	1292	1295	ALS	Disease	MESH:D000690
38474719	1349	1370	metabolic dysfunction	Disease	MESH:D008659
38474719	1376	1396	immune dysregulation	Disease	OMIM:614878
38474719	1561	1564	ALS	Disease	MESH:D000690

